Top Markets
#1 Akedo Akedo +71.59%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.61%
#4 Cross Cross +34.10%
#5 Black Phoenix Black Phoenix +33.95%
#6 Cap Cap +29.61%
#7 Velvet Velvet +26.32%
#8 Ravencoin Ravencoin +17.91%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.35%
#10 DoubleZero DoubleZero +12.07%
Coin of the day
Akedo Akedo
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Rang in Aktien #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Aktienkurs
$0.073
Marktkapitalisierung
$849.99K
Veränderung (1 Tag)
4.29%
Veränderung (1 Jahr)
21.67%
Land
US
Handel Hepion Pharmaceuticals, Inc. (HEPA)

Kategorie

Healthcare
Kursverlauf für Hepion Pharmaceuticals, Inc. (HEPA)
Höchster Schlusskurs: $0.06 am 2026-08-01

Niedrigster Schlusskurs: $815.99K am 2014-02-01
Kursverlauf der Aktie von Hepion Pharmaceuticals, Inc. von 2014 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -13.38%
2025 -99.75%
2024 -83.90%
2023 -47.81%
2022 -72.98%
2021 -35.82%
2020 -64.66%
2019 -80.01%
2018 -87.43%
2017 -77.91%
2016 -3.97%
2015 1.80%
2014 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $503.68 29.05%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $840.68 28.85%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $725.45 6.21%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.40%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $252.06 11.35%
BE